Triple-negative breast cancer is a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2; with poor prognosis, greater relapse risk and worse survival in general. Its proportion in all breast cancer cases ranges from 15 to 20%. Triple negative breast cancer is more prevalent among younger women, particularly African, African-American, Latino and obese women. This observed prevalence, is an age and ethnic related factor which fingers estrogenic agents as a common feature in TNBC occurrence. Inherited variation in the let-7 binding site on the KRAS oncogene has been revealed to confer increased susceptibility to triple negative breast cancer, especially in premenopausal, African-American and Hispanic women. About 15-40% of triple negative breast tumors have BRCA-related epigenetic down-regulation and increased expression of the inhibitors of BRCA1 function, which have be found to be related to indirect Review Article
INTRODUCTION
Breast cancer afflicts approximately 1 in 8 women and is a leading cause of cancer-related mortality. More than 1 million women worldwide are diagnosed with breast cancer each year of which 170,000 cases are referred to as triple negative breast cancer [1] . According to ReisFilho and Tutt [2] , expression profiles of breast cancer exhibit a systematic variation and allow for the classification of breast cancer into five main groups: two estrogen receptor (ER) positive (luminal A and B) and three ER negative groups (normal breastlike, HER2 positive, and 'basallike'). Triple-negative breast cancers form 15 to 20% rough estimate of all breast cancer. They are a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2 [3] . TNBC is more prevalent among younger women [1, 4] , particularly young African, African-American [2, 5] and Latino women [2, 6] . TNBC is more prevalent in among young obese women [1, [6] [7] [8] . The fact that TNBC is associated with younger women may be linked to the presence of high estrogen level in their body system. Hence, it is not surprising that TNBC is associated with been obesed women since obesity results in increased estrogen level. So far, the direct cause of the observed high prevalence in the affected age and ethnic groups has not been confirmed. It is suggested that the stated prevalence might be linked to increased p53 mutations reported in African American women when compared with non-Hispanic white women [9] . It is suggested that the causes may be linked to some environmental or socio-cultural factors. This suggestion is supported by the fact that majority of the familial risk for breast cancer is most likely due to the interaction of low-risk susceptibility genes and non-genetic factors [9] .
A study carried out by Heneghan [10] revealed that an inherited variation in the let-7 binding site on the KRAS oncogene conferred increased susceptibility to breast cancer particularly the 'triple negative' subtype. The KRAS-variant is found in almost 30% of premenopausal ER/PR/HER2 negative breast cancer patients [11] , and in over 20% of unselected TN patients. It has been observed that hormone replacement therapy for postmenopausal women increases the risk of breast cancer 1.2-to 1.7-fold, and administration of progesterone further increases the risk [9] . These reports reinforce the possibility that TNBC may have a strong correlation with hormonal levels in the body, especially estrogen. According to the reports by Minami et al. [11] , the KRAS-variant was also observed to be prevalent in African-American and Hispanic women. This higher prevalence in this ethnic group may be adduced to mutations caused by prior generational gene exposure to environmental estrogenic agents. According to Chen and Russo [1] , over 80% of BRCA-1 mutation carriers are triple negative and approximately 20% of breast cancer patients with mutations in BRCA-1 and BRCA-2 are incapable of DNA repair, because normal BRCA1 and BRCA2 play pivotal part in DNA repair [1] . Carriers of DNA repair mutations among TNBC patients have higher susceptibility to DNA damaging agents [1] . This further fingers mutations resulting from nutritional and environmental factors, and perhaps herbal concoctions as the leading cause of TNBC in the affected ethnic groups. However, such nutritional and environmental factors are yet to be extensively studied and elucidated.
The term triple negative breast cancer encompasses basal-like breast cancer (BLBC) [12] and other uncommon tumors for example, metaplastic tumors and adenoid-cystic tumors [1, 13] . MicroRNAs (miRNAs) are involved in the regulation of key cellular process including development, differentiation, cell proliferation, apoptosis, fat metabolism, angiogenesis, and inflammation [14] . MicroRNAs are a class of endogenous, small, non-coding RNAs that control gene expression by interacting with target mRNAs [1], leading to either mRNA degradation or translational repression [15, 16] 
MICRORNA SYNTHESIS
MicroRNAs (miRNAs) are minute non-coding RNAs that regulate gene expression posttranscriptionally by pairing to 3' untranslated regions (UTRs), coding sequences or 5' UTRs of target messenger RNAs (mRNAs), which in most cases leads to translation inhibition or mRNA degradation [41] [42] [43] . The mature miRNA molecules are produced in a multi-step process.
The DNA sequence is transcribed by RNA polymerase II into a single stranded RNA molecule by hairpin structures known as primary transcripts or pri-miRNAs [44] . The primiRNAs are processed (cutted) into the nucleus by RNAse III Drosha into 70100 nucleotides long fragments called pre-miRNAs. The pre-miRNA molecule is then actively transported to the cytoplasm by a carrier protein [45] . Here, an additional step mediated by the Dicer, generates a double strand.RNA (dsRNA) approximately 22 nucleotides long, including the mature miRNA guide (3p arm) and the complementary passenger strand (5p arm). Once completed, the processing steps, through this mechanism that is not fully characterized yet, the mature miRNA is able to regulate gene expression at posttranscriptional level, binding through partial complementarity the 3' untranslated region (3' UTR) of the target mRNA, and mainly leading to either mRNA degradation or translation inhibition [44, 46] . Depending on the targeted mRNAs, the miRNA action ultimately results in reduced protein levels and profound consequences on cellular homeostasis. In 2004, an in silico study showed that more than half of miRNAs map to genomic regions that are frequently altered in cancer [47] . This include: loss of heterozygosity regions (LOH) (e.g. miR-15a/16-1), amplified regions (e.g. miR-17-92 cluster, miR-155) and breakpoint regions and fragile sites (FRA) (e.g. let-7 family members)
MICRORNA AND EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT)
Tumorigenesis and tumour progression can be seen as evolutionary processes, in which the transformation of a normal cell into a tumor cell involves a number of limiting genetic and epigenetic events that occur in a series of discrete stages [48] . Both functional and observational data implicate alterations in histone modifications, DNA promoter methylation, and non-coding RNA expression in carcinogenesis [49] . On the other hand, due to the wide range of biological functions of miRNAs, analyzing changes in overall miRNA expression levels within human tumors has helped identify miRNA signatures associated with diagnosis, staging, progression, prognosis, and response to treatment [50] . Epigenetics, defined as heritable change in gene activity that is independent of DNA sequence, play a prominent part in cancer initiation and progression [51] . The main epigenetic events that regulate tumor-associated genes are linked to aberrant hypermethylation of tumor-suppressor genes, global DNA hypomethylation item and post-translational modifications of histones and other proteins by acetylation and/or phosphorylation. MiRNAs can be targets of epigenetic events that, in some instances, can explain the perturbation of miRNA expression in cancer [52] .
EMT (epithelial to mesenchymal transition) is the process by which epithelial cells convert to mesenchymal cells and is essential in embryonic development. It appears that aberrant activation of EMT later in life drives cancer progression, and is involved in highly aggressive, poorly differentiated breast cancers with increased potential for metastasis and recurrence [53] . This suggests that EMT may play a critical role in the high metastatic rate and tumour progression in TNBC patient. In TBNC biology, miR-200 is the most fascinating factor where its upregulation correlates well with lymph node positivity and metastasis [54] , but downregulated in metaplastic carcinoma [3, 41] . More so, the miR-200 family, especially miR-200c, inhibits cancer cell migration [55] , invasion [56] [65, 67, 68] . A study carried out by Collin-Burrow [69] demonstrated that HDAC inhibitor (HDACi) regulate microRNAs which in turn regulate the epithelial-to-mesenchymal transition (EMT) [41] in triple-negative breast cancer (TNBC) [3] . This study assessed the microRNA expression profiles of two TNBC cell lines following treatment with HDACi identifying a number of upand down-regulated microRNAs. The overall microRNA profile after HDACi treatment was indicative of a less aggressive phenotype. In this study, miR-126, miR-146b-5p, miR-192, miR-194, miR-215, miR-342.3p and miR-424 were observed to be increased while miR-100, miR106b, miR-125b, miR-331-3p, Let-7i were decreased. Treatment with HDACi also resulted in increased expression of E-cadherin as well as decreased migration of TNBC indicating a reversal of the EMT phenotype (which is associated with metastatic and aggressive disease, of TNBC). [70] .
Moreover miR-181a/b expression sensitizes to cisplatin [71] and to PARP inhibitors [72] by dampening the DNA double-strand-breaks repair, thus representing a possible marker of BRCAness. Estimated levels of miR-181a could play a part in patient selection for PARP inhibitor treatments [3] .
It has been observed that miRNAs such as miR-141-3p, miR-203a, miR-548c-3p, miR-607 and miR-96-5p were appreciably upregulated with concomitant downregulation of miR-181a in triple-negative primary breast cancers when compared with double positive cases [73] . Furthermore, according to the reports of Radojicic et al. [73] , the expression of miR-21, miR-210, and miR-221 have been observed to be higher in the triple-negative (TN) subtype of breast cancer compared with corresponding healthy tissues; while the expression of miR-10b, miR-145, miR-205, miR-122a [74] , miR200a/miR-200b, miR-146b and miR-148a has been observed to be lower [4] . More so, significant downregulation of Let-7c, miR-27b, miR-22, miR-143, miR-30b and miR-30d have been observed in all breast cancer cell lines when compared with non-tumorigenic epithelial MCF-10A cells [4] . In TNBC-associated lymph node metastasis, miRNAs such as miR-424, miR-125a-5P, miR-627, miR-579, let-7g and miR-101 were specifically expressed [3], while miR-424 and miR-125a were specifically expressed only in the metastasis vs. primary tumor and in normal tissue vs. metastasis, respectively [3, 75] . MiR-200b and miR-148a is suggested to target the E2F pathway that is active in poor-prognosis and metastatic breast cancer [4] . MiR-203 has been shown to inhibit cell proliferation and migration, while miR-141-3p inhibits metastasis; upregulation of miR-548c-3p is linked to poor prognosis [4] . Overexpression of miR-155 is observed in TNBC where it results in angiogenesis, tumor growth, metastasis, latestage/high grade tumor and poor prognosis [76] . MiR-155 is epigenetically regulated by BRCA1 and up-regulated in BRCA1-deficient or BRCAmutant breast cancer [77] and initiated by prooncogenic stimuli such as hypoxia, both risk factors for TNBC [3] . Targeting these miRNAs involved in tumour metastasis may lead to a better prognosis in TNBC patients.
One of the most studied microRNAs which consistently are found up-regulated in a wide variety of cancers, including breast cancer, is miR-21 [78] [79] [80] . Up-regulated expression of miR-21 in breast cancer tissues is linked to advanced clinical stage, lymph node positivity, and low survival rate [3, 78, 80] . Some of the microRNAs have shown different expressions not only within the specific subtype of breast cancer but between distinct subtypes of breast cancer as well. MiR-21 is an oncogenic microRNA with antiapoptotic potential which is directly involved in the growth, proliferation, and invasion of the tumor cells by inhibiting the activity of the tumor suppressor genes PDCD4 (programmed cell death-4) and tumor suppressor tropomyosin-1 (TPM1) [81, 82] . Expression levels of miR-21 [83] and miR-29a were significantly higher in triplenegative tumor tissues than in luminal-B tumor tissues [84] . Another microRNA which has been reported as being expressed differentially in the TN tumors is miR-31, which is downregulated as a result of epigenetical hypermethylation of LOC554202 [3, 73, 85] . MiR-31 play an important part in metastastic process and its upregulation initiates apoptosis and increases chemo-and radiosensitivity in TNBC cell lines by direct inhibition of PRKCE [3, 86] . Inverse correlation between miR-31 and Bcl-2 was found by exploiting a public dataset of breast cancer patients [87] . Regulation of Bcl-2 oncogene as a therapeutic measure could alter miR-31 effects and perhaps increase the overall survival of TNBC patients.
PROGNOSTIC AND THERAPEUTIC MARKERS IN TBNC
Even though MiRNAs have been proposed as potential therapeutic tool, there are few documented accomplishments in that regard [93] . There are two major strategies to target miRNAs expression in cancer: a) direct strategies employs oligonucleotides or virus based constructs to either block the expression of an oncogenic miRNA or to reintroduce a tumor suppressor miRNA lost in cancer [93] ; b) indirect strategy involves the use of drugs to modulate miRNAs expression by targeting their transcription and processing. Glyceollins, antiestrogenic agents, exert antitumor activity in TNBC [89] . Decreased expression of miR5425p, with overexpression of NME1, signifies a reversal of EMT and a suppression of metastasis by glyceollins. A second target identified through proteomics approach is vimentin, whose expression was down regulated more than 13 fold by glyceollins. Vimentin is a marker for epithelial-to-mesenchymal transition and is highly expressed in numerous TNBCs [94] . Vimentin is a proven target of miR30d and a predicted target of miR138, both found to be appreciably elevated by glyceollins [95] . These data suggest that the effects of glyceollins on TNBC cell lines are achieved via regulation of miRs, which in turn regulate known oncogenes and tumor suppressors [89] . Among the most down regulated miRs following treatment with glyceollins were 193a5p, 197, 224, 4865p, and 5425p, all of which have been associated with cancer progression [89] . The link between specific miRNAs with ER, PR and HER2 status reveals the role of miRNAs in disease classification of breast cancer. Decreased expression of miRNA-342 in TNBC tumors, increased miRNA-342 expression in the Luminal-B tumors, and down regulated miRNA-520g in ER-and PR-positive tumors indicate that deregulated miRNA expression is not only an indicator for poorer prognosis of breast cancer, but also future target for therapy [96] . Current studies [1, [97] [98] [99] [100] [101] [102] [103] have shown that several miRNAs play critical roles in the modulation of ERα expression and ERα-mediated signaling in breast cancer cells.
Some microRNAs have been recognized as prognostic markers in breast cancer. For instance, overexpressions of miR-16, miR-155 or miR-374 are associated with better prognosis while underexpression of miR-125b is linked to worse prognosis. Three "risk-associated" miRs (miR-125b, miR-655 and miR-421) and four "protective" miRNAs have been revealed (miR-16, miR-374a, miR-374b and miR-497) are negatively and positively associated with distant disease free survival (DDFS), respectively [104] . MiR-210 over-expressed in TNBC compared to ER+ [105] , is an independent prognostic factor in TNBC; decreased levels of miR-210 showed better distant-free-survival (DFS) in TNBC and no relapse 5 years following surgery in node negative TNBC [106] . MiR-34b, a member of the p53-regulated miR-34 family [107] , is negatively associated with DFS and overall survival (OS) [3, 108] .
In TNBC, XBP1 has a critical role in the tumorigenicity and progression. In breast cancer cell line models, decreased levels of XBP1 inhibits tumour growth and tumour relapse and reduced the CD44 high CD24 low population [109] . Tumour cells expressing CD44 high CD24 low have been shown to mediate tumour relapse in some instances [110] [111] [112] . XBP1 pathway activation is associated with poor patient survival in TNBC patients, indicating that unfolded protein response (UPR) inhibitors in combination with standard chemotherapy may improve the effectiveness of antitumour therapies [109] . Recent findings suggest that XBP1 branch of the UPR has a major role in TNBC and signify that targeting this pathway may offer alternative treatment strategies for this aggressive subtype of breast cancer [109] .
ID4 is a transcription factor of the helix-loop-helix protein family whose expression is inversely correlated with that of ER. ID4 is expressed in breast cancer, particularly triple negative breast cancers [113] and can negatively modulate BRCA1 expression [114] . Increased expression of ID proteins has been reported in several cancer types [115] [116] [117] and has been found associated with loss of differentiation, enhanced malignancy and aggressive clinical behavior [117, 118] . ID4 is involved in mammalian embryogenesis, angiogenesis and in the maintenance of cancer stem cells [92, 119, 120] . Furthermore, ID4 overexpression is linked to the anchorage-independent growth exhibited by breast cancer cells [70] , while its underexpression dictate their morphological change to large and flat epithelial phenotypes [121] . The finding that ID4 is a negative modulator of the tumor suppressor gene BRCA1 [3, [122] [123] [124] supports an oncogenic function of ID4. In breast cancer, miR-342 which has been speculated to have a role in reducing the expression of BRCA1 [125] is associated with better prognosis [126, 127] . The reports of Crippa et al. [114] reported an inverse correlation between ID4 and miR-342 and also between ID4 and BRCA1 expression [114] . According to their reports [114] , overexpression of miR-342 in breast cancer cells depleted ID4 and induced BRCA1 overexpression, suggesting a viable position of this mechanism in breast cancer. The inverse correlation between ID4, miR-342 and BRCA1 expressions in TNBC could be used as a prognostic tool or marker in TNBC management. This review suggests that inhibiting miRNA target oncogenes may provide definite framework for clinical breast cancer therapy [114] .
CONCLUSION
The correlation between TNBC, BRCA mutation and KRAS oncogene suggests that age, hormone levels and environmental factor play critical roles in the emergence of Triple-negative breast cancer in certain ethnic groups. The age, hormonal, ethnic and environmental factors, one way or the other, directly or indirectly, affect the expressions of some pro-oncogenes and miRNAs in biological systems. The discovery of miRNAs which function by modulation of some target oncogenes have provided prognostic markers and created future possible therapeutic frameworks for TNBC, which is due to the fact that certain target oncogenes have been successfully altered through inhibitory systematic pathways. This review gives knowledge of the characteristic features of TNBC and its risk factors, especially the BRCA1 mutation, KRAS and ID4 oncogenes, and the place of Epithelialto-Mesenchymal Transition (EMT) in TNBC progression. However, more studies on nutritional and environmental factors are required to unveil the direct relationship between TNBC and ethnicity.
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